NCT00084630View on ClinicalTrials.gov

Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2004

Primary Completion Date

July 31, 2007

Conditions

Adult FibrosarcomaDermatofibrosarcoma ProtuberansRecurrent Adult Soft Tissue SarcomaStage IV Adult Soft Tissue Sarcoma

Interventions

DRUG

imatinib mesylate

Given orally

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

78245

Southwest Oncology Group, San Antonio

All Listed Sponsors

lead

National Cancer Institute (NCI)

NIH

NCT00084630 - Imatinib Mesylate in Treating Patients With Locally Recurrent or Metastatic Dermatofibrosarcoma Protuberans | Biotech Hunter | Biotech Hunter